513 Elevated Osteopontin Levels in Patients With Chronic Heart Failure: Describing a Specific Physiopathologal Process
Kay Roy, Jocelyn Dupuis(Montreal Heart Institute), Mark Liszkowski(Montreal Heart Institute), Lucie Blondeau(Montreal Heart Institute), Anique Ducharme(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Jacques R. Rouleau, Simon de Denus(Montreal Heart Institute), Martin G. Sirois(Montreal Heart Institute), Michelle K. White(GroundMetrics (United States)), Normand Racine(Montreal Heart Institute), J. Lavoie
Cited by 2
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
|Circulation|2014|1k